Pfizer has pursued deals of all sizes to build new revenue streams, but the outlook underscores that those investments are still some distance from paying off.
The FDA is reportedly preparing to add what's known as a "black box" warning to Covid shots by the end of the year, marking a major shift in vaccine oversight.
The drugmaker is betting big on retatrutide as the next pillar of its obesity portfolio after its weight loss injection Zepbound and its upcoming pill.
The announcement comes weeks after President Donald Trump inked deals with Eli Lilly and Novo Nordisk to make their GLP-1 drugs easier for Americans to access.
The announcements come days after President Donald Trump struck deals with Novo Nordisk and Eli Lilly to make their GLP-1s easier for Americans to access.
Novo Nordisk released new data to underscore its pill's safety and effectiveness, while Trump is asked whether private plans could see lower GLP-1 costs.
Medicare will start covering obesity drugs for the first time, which could open access to millions of seniors and spur more private insurers to follow suit.
